Adipose-derived stem cell transplantation improves learning and memory via releasing neurotrophins in rat model of temporal lobe epilepsy

Wang, Lili; Zhao, Yingchun; Xiao-chun, Pan; Zhang, Yu; Lin, Lin; Wu, Ying; Huang, Yong; He, Hua

doi:10.1016/j.brainres.2020.147121

Cited by 20 publications

(26 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The study showed that CD105 + ADSCs had high growth rate and differentiation ability (Lv et al., 2012). Human ADSCs with higher expression of CD90 and CD105 could release neurotrophins such as brain‐derived neurotrophic factor (BDNF), neurotrophin‐3 (NT3), and neurotrophin‐4 (NT4) thereby preventing epilepsy (Wang et al., 2021).…”

Section: Discussionmentioning

confidence: 99%

Intracerebral transplantation of autologous adipose‐derived stem cells for chronic ischemic stroke: A phase I study

Chiu

Baskaran

Tsai

et al. 2021

J Tissue Eng Regen Med

View full text Add to dashboard Cite

Current therapy does not provide significant benefits for patients with chronic stroke. Pre-clinical studies suggested that autologous adipose-derived stem cells have benefits for the treatment of chronic stroke. This Phase I open-label study was conducted to demonstrate the safety and efficacy of autologous adipose-derived stem cells (GXNPC1) in chronic stroke. Three patients with chronic stroke were treated with stereotactic implantation of autologous adipose-derived stem cells (1 � 10 8 cells). The primary endpoints of safety evaluation included adverse events, over a 6 months post-implantation period. The secondary endpoints included improvements in neurological functions. Evolutional change of brain parenchyma was also followed with magnetic resonance imaging (MRI). All three participants improved significantly at 6 months follow-up. The extent of improvement from pretreatment was: National Institutes of Health Stroke Scale improved 5-15 points, Barthel Index: 25-50 points, Berg balance scale 0-21 points and Fugl-Meyer modified sensation 3-28 points. All three patients had signal change along the implantation tract on MRI one month after surgery. There is no related safety issue through 6 months observation. Clinical measures of neurological symptoms of these patients with chronic stroke improved at 6 months without adverse effects after implantation of autologous adipose-derived stem cells (GXNPC1), which might be correlated with post-implantation changes on brain MRI.

show abstract

Section: Discussionmentioning

confidence: 99%

Intracerebral transplantation of autologous adipose‐derived stem cells for chronic ischemic stroke: A phase I study

Chiu

Baskaran

Tsai

et al. 2021

J Tissue Eng Regen Med

View full text Add to dashboard Cite

show abstract

“…Cell therapy for epilepsy includes a variety of approaches, including the use of MSCs ( Abdanipour et al, 2011 ; Mohammed et al, 2014 ; Park et al, 2015 ; Hlebokazov et al, 2017 , 2021 ; Fukumura et al, 2018 ; Salem et al, 2018 ; Melin et al, 2019 ; Szczepanik et al, 2020 ; Wang et al, 2021 ), mononuclear cells ( Costa-Ferro et al, 2010 ; Leal et al, 2014 ; DaCosta et al, 2018 ), cells of the nervous system ( Baraban et al, 2009 ; Waldau et al, 2010 ; Cunningham et al, 2014 ; de Gois da Silva et al, 2018 ; Upadhya et al, 2019 ), and encapsulated cells expressing various therapeutic factors ( Kanter-Schlifke et al, 2009 ; Kuramoto et al, 2011 ; Nikitidou et al, 2014 ; Falcicchia et al, 2018 ; Paolone et al, 2019 ), as well as exosomes ( Long et al, 2017 ; Xian et al, 2019 ). Cell therapy is an alternative treatment that can be used to reduce the incidence rate of seizures in epilepsy, including drug-resistant epilepsy, as shown in several clinical studies ( Hlebokazov et al, 2017 , 2021 ; DaCosta et al, 2018 ; Milczarek et al, 2018 ; Szczepanik et al, 2020 ).…”

Section: Cell Therapymentioning

confidence: 99%

Gene and Cell Therapy for Epilepsy: A Mini Review

Shaimardanova

Chulpanova

Mullagulova

et al. 2022

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Epilepsy is a chronic non-infectious disease of the brain, characterized primarily by recurrent unprovoked seizures, defined as an episode of disturbance of motor, sensory, autonomic, or mental functions resulting from excessive neuronal discharge. Despite the advances in the treatment achieved with the use of antiepileptic drugs and other non-pharmacological therapies, about 30% of patients suffer from uncontrolled seizures. This review summarizes the currently available methods of gene and cell therapy for epilepsy and discusses the development of these approaches. Currently, gene therapy for epilepsy is predominantly adeno-associated virus (AAV)-mediated delivery of genes encoding neuro-modulatory peptides, neurotrophic factors, enzymes, and potassium channels. Cell therapy for epilepsy is represented by the transplantation of several types of cells such as mesenchymal stem cells (MSCs), bone marrow mononuclear cells, neural stem cells, and MSC-derived exosomes. Another approach is encapsulated cell biodelivery, which is the transplantation of genetically modified cells placed in capsules and secreting various therapeutic agents. The use of gene and cell therapy approaches can significantly improve the condition of patient with epilepsy. Therefore, preclinical, and clinical studies have been actively conducted in recent years to prove the benefits and safety of these strategies.

show abstract

“…By increasing BDNF levels, EPCs may mitigate the neurological complications of epilepsy, as well as neuropsychiatric comorbidities like anxiety, PTSD, and cognitive impairments. Additionally, rats treated with intrahippocampal KA received adipose-derived stem cells (ADSCs) ( Wang et al, 2021 ). The ADSCs demonstrated significant differentiative capacity, as observed with the high levels of Tuj1, MAP2, NeuN, and PSD-95 expression in these cells ( Wang et al, 2021 ).…”

Section: The Efficacy Of Stem Cells In Alleviating the Neuropsychiatrmentioning

confidence: 99%

“…Additionally, rats treated with intrahippocampal KA received adipose-derived stem cells (ADSCs) ( Wang et al, 2021 ). The ADSCs demonstrated significant differentiative capacity, as observed with the high levels of Tuj1, MAP2, NeuN, and PSD-95 expression in these cells ( Wang et al, 2021 ). Importantly, the rats completed the Morris water maze task more effectively following ADSC treatment, indicating ameliorated learning and memory deficits spurred by epilepsy ( Wang et al, 2021 ).…”

Section: The Efficacy Of Stem Cells In Alleviating the Neuropsychiatrmentioning

confidence: 99%

“…The ADSCs demonstrated significant differentiative capacity, as observed with the high levels of Tuj1, MAP2, NeuN, and PSD-95 expression in these cells ( Wang et al, 2021 ). Importantly, the rats completed the Morris water maze task more effectively following ADSC treatment, indicating ameliorated learning and memory deficits spurred by epilepsy ( Wang et al, 2021 ). The ADSCs also secreted neurotrophic factors like BDNF, NT3, and NT4, which may play a role in alleviating cognitive impairments accompanying epilepsy ( Wang et al, 2021 ).…”

Section: The Efficacy Of Stem Cells In Alleviating the Neuropsychiatrmentioning

confidence: 99%

See 1 more Smart Citation

Multipronged Attack of Stem Cell Therapy in Treating the Neurological and Neuropsychiatric Symptoms of Epilepsy

et al. 2021

View full text Add to dashboard Cite

Epilepsy stands as a life-threatening disease that is characterized by unprovoked seizures. However, an important characteristic of epilepsy that needs to be examined is the neuropsychiatric aspect. Epileptic patients endure aggression, depression, and other psychiatric illnesses. Therapies for epilepsy can be divided into two categories: antiepileptic medications and surgical resection. Antiepileptic drugs are used to attenuate heightened neuronal firing and to lessen seizure frequency. Alternatively, surgery can also be conducted to physically cut out the area of the brain that is assumed to be the root cause for the anomalous firing that triggers seizures. While both treatments serve as viable approaches that aim to regulate seizures and ameliorate the neurological detriments spurred by epilepsy, they do not serve to directly counteract epilepsy’s neuropsychiatric traits. To address this concern, a potential new treatment involves the use of stem cells. Stem cell therapy has been employed in experimental models of neurological maladies, such as Parkinson’s disease, and neuropsychiatric illnesses like depression. Cell-based treatments for epilepsy utilizing stem cells such as neural stem cells (NSCs), mesenchymal stem cells (MSCs), and interneuron grafts have been explored in preclinical and clinical settings, highlighting both the acute and chronic stages of epilepsy. However, it is difficult to create an animal model to capitalize on all the components of epilepsy due to the challenges in delineating the neuropsychiatric aspect. Therefore, further preclinical investigation into the safety and efficacy of stem cell therapy in addressing both the neurological and the neuropsychiatric components of epilepsy is warranted in order to optimize cell dosage, delivery, and timing of cell transplantation.

show abstract

Adipose-derived stem cell transplantation improves learning and memory via releasing neurotrophins in rat model of temporal lobe epilepsy

Cited by 20 publications

References 22 publications

Intracerebral transplantation of autologous adipose‐derived stem cells for chronic ischemic stroke: A phase I study

Intracerebral transplantation of autologous adipose‐derived stem cells for chronic ischemic stroke: A phase I study

Gene and Cell Therapy for Epilepsy: A Mini Review

Multipronged Attack of Stem Cell Therapy in Treating the Neurological and Neuropsychiatric Symptoms of Epilepsy

Contact Info

Product

Resources

About